Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial

• Päätekijät: Isaac Weber (Tekijä), Caterina Zagona-Prizio (Tekijä), Torunn E Sivesind (Tekijä), Madeline Adelman (Tekijä), Mindy D Szeto (Tekijä), Ying Liu (Tekijä), Stefan H Sillau (Tekijä), Jacquelyn Bainbridge (Tekijä), Jost Klawitter (Tekijä), Cristina Sempio (Tekijä), Cory A Dunnick (Tekijä), Maureen A Leehey (Tekijä), Robert P Dellavalle (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: JMIR Publications, 2024-03-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

BackgroundSeborrheic dermatitis (SD) affects 18.6%-59% of persons with Parkinson disease (PD), and recent studies provide evidence that oral cannabidiol (CBD) therapy could reduce sebum production in addition to improving motor and psychiatric symptoms in PD. Therefore, oral CBD could be useful for...